Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 28, 2014; 20(4): 1067-1073
Published online Jan 28, 2014. doi: 10.3748/wjg.v20.i4.1067
Published online Jan 28, 2014. doi: 10.3748/wjg.v20.i4.1067
Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer
Xin Wang, Jing Jin, Ye-Xiong Li, Hua Ren, Hui Fang, Shu-Lian Wang, Yue-Ping Liu, Wei-Hu Wang, Zi-Hao Yu, Yong-Wen Song, Xin-Fan Liu, Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Author contributions: Wang X, Jin J and Li YX designed the research; Wang X, Jin J, Li YX, Ren H, Fang H, Wang SL, Liu YP, Wang WH, Yu ZH, Song YW and Liu XF performed the research; Wang X collected and analyzed the data and wrote the paper; Jin J and Li YX modified the paper.
Supported by Beijing Hope Run Special Fund, No. LC2007A03
Correspondence to: Jing Jin, MD, Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli 17, Chaoyang District, Beijing 100021, China. jingjin1025@163.com
Telephone: +86-10-87787658 Fax: +86-10-67706153
Received: September 27, 2013
Revised: November 14, 2013
Accepted: December 12, 2013
Published online: January 28, 2014
Processing time: 121 Days and 18.9 Hours
Revised: November 14, 2013
Accepted: December 12, 2013
Published online: January 28, 2014
Processing time: 121 Days and 18.9 Hours
Core Tip
Core tip: Postoperative chemoradiotherapy is a good option for patients with locally advanced, gastric cancer who have undergone R0 and D0-1 lymphadenectomy. To avoid acute side effects and make the drug safer, a combination of the use of advanced techniques such as intensity modulated radiotherapy and mature chemotherapy regimens with capecitabine is highly recommended, especially in China which accounts for 40% of the world’s gastric cancer patients. The aim of this single-institution, phase I, clinical trial was to assess the feasibility and toxicity of a postoperative regimen involving dose escalation of capecitabine combined with IMRT for locally advanced gastric cancer.